The Patent Finder

Vitaeris Inc.

14 patents currently held · Updated Nov 16, 2026
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
14
Ending by 2030
Mar 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Antibodies to IL-6 and use thereof (US 10,344,086) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due May 28, 2027
    The maintenance fee for Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies (US 11,827,700) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,913,794Antibodies to IL-6 and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,725,509Expression Vectors Containing Isolated Nucleic Acids Encoding Anti-Human IL-6 Antibody
In force
 · Medium confidence
In forceMedium confidence
US 9,834,603Antibodies to IL-6 and Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,227,404Antagonists of IL-6 to Raise Albumin And/Or Lower CRP
In force
 · Medium confidence
In forceMedium confidence
US 10,233,239Isolated Host Cells Expressing ANTI-IL-6 Antibodies
In force
 · Medium confidence
In forceMedium confidence
US 10,344,086Antibodies to IL-6 and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,759,853Antibodies to IL-6 and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,178,101Use of ANTI-IL-6 Antibodies Having Specific Binding Properties to Treat Cachexia
In force
 · Medium confidence
In forceMedium confidence
US 8,062,864Nucleic Acids Encoding Antibodies to IL-6, and Recombinant Production of ANTI-IL-6 Antibodies
In force
 · Medium confidence
In forceMedium confidence
US 9,741,198Gaming Device with Special Symbol
In force
 · Medium confidence
In forceMedium confidence
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 14 patents in force now held by others · 29 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited